tirzepatide surpass 2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial SURPASS 2: Tirzepatide Versus Once-Weekly
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6























